Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults

Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R. Cai, Gordon Chau, Shane Cloney-Clark, Mark Eickhoff, Raj Kalkeri, Irene McKnight, Joyce Plested, Mingzhu Zhu, Lisa Dunkle the 2019nCoV-307 study team
doi: https://doi.org/10.1101/2023.03.16.23287030

Article usage

Article usage: March 2023 to November 2024

AbstractFullPdf
Mar 202378237168
Apr 20232912276
May 202395630
Jun 2023117536
Jul 202399120
Aug 2023671216
Sep 202386413
Oct 202389715
Nov 202355913
Dec 202329414
Jan 20243538
Feb 202435216
Mar 202441311
Apr 20242439
May 20243515
Jun 2024431321
Jul 202431722
Aug 202429317
Sep 202428611
Oct 20242616
Nov 20241927
Back to top
Posted March 20, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults
Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R. Cai, Gordon Chau, Shane Cloney-Clark, Mark Eickhoff, Raj Kalkeri, Irene McKnight, Joyce Plested, Mingzhu Zhu, Lisa Dunkle
medRxiv 2023.03.16.23287030; doi: https://doi.org/10.1101/2023.03.16.23287030
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area